Form 4: Prime Medicine CFO Allan Reine Reports Stock Option Grant

Chief Financial Officer Allan Reine of Prime Medicine, Inc. reports the acquisition of stock options.

Summary

• On February 27, 2025, Allan Reine, the Chief Financial Officer of Prime Medicine, Inc., was granted stock options to purchase 275,000 shares of common stock.
• The exercise price of these options is $2.42 per share.
• The options vest in equal monthly installments over a four-year period, beginning on February 27, 2025, contingent upon continued service.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management incentives with shareholder value.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron routinely use stock options to incentivize their executives.
• The size of the grant (275,000 shares) would need to be compared to grants given to CFOs at companies of similar size and stage of development to determine if it is in line with industry standards.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the CFO's interests with the company's long-term success.
• Employees may see this as a sign of confidence in the company's future.

Key Dates